Semaglutide vs Tirzepatide
Semaglutide and tirzepatide are both injectable incretin-based therapies with FDA approval for type 2 diabetes and obesity — but their receptor targets differ in a clinically meaningful way. Semaglutide is a GLP-1 receptor agonist; tirzepatide is a dual GIP/GLP-1 receptor agonist. Head-to-head trial data (SURMOUNT-5) now show tirzepatide produces meaningfully greater weight loss, though both are highly effective and have large RCT evidence bases.
Side-by-side comparison
| Property | Semaglutide | Tirzepatide |
|---|---|---|
| Mechanism class | GLP-1 receptor agonist (single agonist) | Dual GIP/GLP-1 receptor agonist |
| FDA status | FDA-approved — Ozempic (T2DM), Wegovy (obesity), Rybelsus (oral T2DM) | FDA-approved — Mounjaro (T2DM), Zepbound (obesity) |
| Evidence tier | Tier 1 (multiple Phase 3 RCTs, FDA label) | Tier 1 (multiple Phase 3 RCTs, FDA label) |
| Typical dosing | 0.5–2.4 mg/week SC; 3–14 mg/day oral | 5–15 mg/week SC |
| Half-life | ~1 week | ~5 days |
| Common side effects |
|
|
| Common stacks | Resistance training + high-protein diet (lean mass preservation) | Resistance training + high-protein diet (lean mass preservation) |
| Approx. cost | ~$900–1,100/month brand; ~$300–500/month compounded | ~$1,000–1,300/month brand; ~$300–600/month compounded |
Key differences
- 1
Tirzepatide activates both GIP and GLP-1 receptors; semaglutide activates GLP-1 only. The added GIP agonism is the primary pharmacological reason tirzepatide produces greater average weight loss in comparative trials.
- 2
SURMOUNT-5 (head-to-head RCT) showed tirzepatide 10–15 mg achieved ~20% body weight loss vs ~14% for semaglutide 2.4 mg at 72 weeks in adults with obesity — a statistically and clinically significant difference.
- 3
Tirzepatide has a half-life of ~5 days vs ~7 days for semaglutide; both support once-weekly subcutaneous injection.
- 4
Real-world cohort data suggest tirzepatide users report lower rates of nausea and vomiting at equivalent therapeutic stages, though both share a class-level GI side effect profile that is managed through structured dose escalation.
- 5
Compounded semaglutide has faced greater FDA scrutiny and quality-control concerns; both compounded forms are substantially less expensive than brand products but carry regulatory complexity.
Which might be better for…
Type 2 diabetes management
Both carry FDA approval for T2DM with robust Phase 3 HbA1c-reduction data. Tirzepatide may produce marginally greater glycemic control due to its dual GIP/GLP-1 mechanism, but both are highly effective first-line pharmacological options alongside lifestyle modification. Choice often comes down to insurance coverage, cost, and individual tolerability.
Obesity and weight loss
For individuals with BMI ≥30 (or ≥27 with weight-related comorbidities), tirzepatide's superior average weight loss in trial data makes it a stronger pharmacological option where access and cost are comparable. Semaglutide 2.4 mg (Wegovy) remains highly effective and has a longer commercial track record. Both require sustained use — weight returns when treatment is discontinued.
Tolerability and prior GLP-1 experience
Patients who experienced significant GI side effects on semaglutide may find tirzepatide's real-world tolerability profile modestly better, though individual response varies and is not guaranteed. Both drugs use the same slow dose-escalation strategy to minimize GI burden. A prescriber familiar with both can help select based on prior GLP-1 exposure and metabolic priorities.